← Product Code [OCC](/productcode/OCC) · K262789

# SimplicityDx Panel FluA/FluB/RSV (K262789)

_Molecular Designs · OCC · Nov 4, 2026 · Microbiology · SESE_

**Canonical URL:** https://fda.innolitics.com/device/K262789

## Device Facts

- **Applicant:** Molecular Designs
- **Product Code:** [OCC](/productcode/OCC.md)
- **Decision Date:** Nov 4, 2026
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 866.3980
- **Device Class:** Class 2
- **Review Panel:** Microbiology
- **Attributes:** PCCP

## Indications for Use

The SimplicityDx Panel FluA/FluB/RSV assay is a multiplex real-time reverse transcriptase polymerase chain reaction (RT-PCR) in vitro diagnostic test intended for the simultaneous qualitative detection and differentiation of influenza A, influenza B, and/or respiratory syncytial virus (RSV). Nucleic acids are isolated and purified from anterior nasal (AN) swab specimens obtained from individuals exhibiting signs and symptoms of a respiratory tract infection. Clinical signs and symptoms of respiratory viral infection due to influenza A, influenza B, and RSV can be similar. The test is intended to aid in the differential diagnosis of influenza A, influenza B, and RSV in humans in conjunction with other clinical, epidemiologic and laboratory findings and is not intended to detect influenza C. Nucleic acids from the viral organisms identified by this assay are generally detectable in AN swab specimens during the acute phase of infection. Positive results of a specific target are indicative of the presence of viral RNA and may not be the definitive cause of disease. Positive results do not rule out co-infection with other pathogens. Negative results do not preclude influenza A, influenza B, and RSV infection and should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Performance characteristics for influenza A were established when influenza A/H3 and A/H1 were the predominant influenza A viruses in circulation. Performance of detecting influenza A may vary if other influenza A strains are circulating, or a novel influenza A virus emerges. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health departments for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

## Device Story

Multiplex RT-PCR assay for qualitative detection/differentiation of Flu A, Flu B, and RSV RNA in anterior nasal swabs. Input: extracted nucleic acids from patient samples. Process: magnetic bead-based extraction (SimplicityDx Extraction System) followed by real-time RT-PCR amplification and detection (QuantStudio 5 Dx System). Output: qualitative positive/negative results for each target. Used in clinical laboratories by trained personnel. Results aid clinicians in differential diagnosis alongside clinical/epidemiological findings. Benefits include rapid, simultaneous identification of common respiratory viruses to inform patient management.

## Clinical Evidence

Prospective clinical study of 914 evaluable anterior nasal swab specimens (fresh and frozen). Compared against an FDA-cleared molecular respiratory panel. Overall PPA: 97.3% (Flu A), 100% (Flu B), 100% (RSV). Overall NPA: 99.6% (Flu A), 99.9% (Flu B), 98.4% (RSV).

## Technological Characteristics

Multiplex RT-PCR assay. Targets: Flu A (VIC), Flu B (JUN), RSV (Cy5), RNase P (Quasar 705). Requires SimplicityDx Extraction System (magnetic bead capture) and QuantStudio 5 Dx Real-Time PCR System. Software: Diomni Enterprise Software v2+ with 'SABR IVD v0' assay definition file. Prescription use, in vitro diagnostic.

## Regulatory Identification

A respiratory viral panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple viral nucleic acids extracted from human respiratory specimens or viral culture. The detection and identification of a specific viral nucleic acid from individuals exhibiting signs and symptoms of respiratory infection aids in the diagnosis of respiratory viral infection when used in conjunction with other clinical and laboratory findings. The device is intended for detection and identification of a combination of the following viruses:(1) Influenza A and Influenza B; (2) Influenza A subtype H1 and Influenza A subtype H3; (3) Respiratory Syncytial Virus subtype A and Respiratory Syncytial Virus subtype B; (4) Parainfluenza 1, Parainfluenza 2, and Parainfluenza 3 virus; (5) Human Metapneumovirus; (6) Rhinovirus; and (7) Adenovirus.

## Special Controls

*Classification.* Class II (special controls). The special controls are:(1) FDA's guidance document entitled “Class II Special Controls Guidance Document: Respiratory Viral Panel Multiplex Nucleic Acid Assay;”
(2) For a device that detects and identifies Human Metapneumovirus, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Human Metapneumovirus (hMPV) Using Nucleic Acid Assays;” and
(3) For a device that detects and differentiates Influenza A subtype H1 and subtype H3, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Detection and Differentiation of Influenza A Virus Subtypes Using Multiplex Nucleic Acid Assays.” See § 866.1(e) for the availability of these guidance documents.

## Predicate Devices

- DiaSorin Simplexa Flu A/B & RSV Direct Gen II ([K201505](/device/K201505.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{1}

[LOGO]

FDA

U.S. FOOD & DRUG

ADMINISTRATION

### 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY

ASSAY ONLY

### I Background Information:

#### A 510(k) Number

K262789

#### B Applicant

Molecular Designs

#### C Proprietary and Established Names

SimplicityDx Panel FluA/FluB/RSV

#### D Regulatory Information

|  Product Code(s) | Classification | Regulation Section | Panel  |
| --- | --- | --- | --- |
|  OCC | Class II | 21 CFR 866.3980 - Respiratory Viral Panel Multiplex Nucleic Acid Assay | MI  |

### II Submission/Device Overview:

#### A Purpose for Submission:

The purpose of this submission is to show that SimplicityDx Panel FluA/FluB/RSV is substantially equivalent to the DiaSorin Simplexa Flu A/B & RSV Direct Gen II (K201505) and to obtain clearance for the SimplicityDx Panel FluA/FluB/RSV. Additionally, to establish a Predetermined Change Control Plan (PCCP) to validate certain future device modifications for the SimplicityDx Panel FluA/FluB/RSV.

#### B Measurand:

- Influenza A RNA
- Influenza B RNA
- Respiratory Syncytial Virus (RSV) RNA

Food and Drug Administration

10903 New Hampshire Avenue

Silver Spring, MD 20993-0002

www.fda.gov

{2}

### C Type of Test:

Qualitative real-time reverse transcription polymerase chain reaction (RT-PCR)

## III Intended Use/Indications for Use:

### A Intended Use(s):

See Indications for Use below.

### B Indication(s) for Use:

The SimplicityDx Panel FluA/FluB/RSV assay is a multiplex real-time reverse transcriptase polymerase chain reaction (RT-PCR) in vitro diagnostic test intended for the simultaneous qualitative detection and differentiation of influenza A, influenza B, and/or respiratory syncytial virus (RSV). Nucleic acids are isolated and purified from anterior nasal (AN) swab specimens obtained from individuals exhibiting signs and symptoms of a respiratory tract infection. Clinical signs and symptoms of respiratory viral infection due to influenza A, influenza B, and RSV can be similar. The test is intended to aid in the differential diagnosis of influenza A, influenza B, and RSV in humans in conjunction with other clinical, epidemiologic and laboratory findings and is not intended to detect influenza C.

Nucleic acids from the viral organisms identified by this assay are generally detectable in AN swab specimens during the acute phase of infection. Positive results of a specific target are indicative of the presence of viral RNA and may not be the definitive cause of disease. Positive results do not rule out co-infection with other pathogens. Negative results do not preclude influenza A, influenza B, and RSV infection and should not be used as the sole basis for diagnosis, treatment, or other patient management decisions.

Performance characteristics for influenza A were established when influenza A/H3 and A/H1 were the predominant influenza A viruses in circulation. Performance of detecting influenza A may vary if other influenza A strains are circulating, or a novel influenza A virus emerges. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health departments for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

### C Special Conditions for Use Statement(s):

For prescription use

For *in vitro* diagnostic use

### D Special Instrument Requirements:

The assay is intended for use with the Simplicity Dx Extraction System and QuantStudio 5 Dx Real-Time PCR System with Diomni Enterprise Software version 2 or higher (Thermo Fisher Scientific) with "SABR IVD v0' assay definition file installed.

## IV Device/System Characteristics:

K262789 - Page 2 of 22

{3}

# A Device Description:

The SimplicityDx Panel FluA/FluB/RSV is a multiplex real-time reverse transcriptase polymerase chain reaction (RT-PCR) in vitro diagnostic test intended for the simultaneous qualitative detection and differentiation of influenza A (Flu A), influenza B (Flu B), and/or respiratory syncytial virus (RSV) in anterior nasal swab specimens collected from individuals with signs and symptoms of upper respiratory tract infection.

The following organisms are identified using the SimplicityDx Panel FluA/FluB/RSV:

- Influenza A
- Influenza B
- RSV

The SimplicityDx Panel FluA/FluB/RSV aids in the diagnosis of influenza A, influenza B, and/or RSV infections if used in conjunction with other clinical and epidemiological information, and laboratory findings. Influenza A, influenza B, and RSV viral RNA are generally detectable in nasal specimens during the acute phase of infection. The assay is intended for use with the Simplicity Dx Extraction System and QuantStudio 5 Dx Real-Time PCR System. The product contains primers and probes used in RT-PCR for the in vitro qualitative detection and differentiation of influenza A RNA, influenza B RNA, and/or RSV RNA in upper respiratory specimens.

# B Principle of Operation:

The SimplicityDx Panel FluA/FluB/RSV plate detects and differentiates viral RNA from Influenza A, Influenza B, and RSV that has been extracted from patient samples using the SimplicityDx Extraction System. A multiplex real-time PCR reaction amplifies viral targets if they are present in the reaction. The assay also contains an endogenous sample processing control, RNase P (RP), which ensures that sufficient sample has been collected and that the extraction process for each sample proceeded without issues. The PCR reaction is performed using the Thermo Fisher QuantStudio 5 Dx Real-Time PCR System. Identification of the viruses occurs by the binding of sequence-specific primers and probes to the viral target of interest. The probes are fluorescently labeled to allow for differentiation of the various targets.

|  Target | Dye  |
| --- | --- |
|  Influenza A | VIC  |
|  Influenza B | JUN  |
|  RSV | Cy5  |
|  RP | Quasar 705  |

Sample Collection: Anterior nasal swabs from symptomatic patients are collected and stored/transported in UTM.

Nucleic Acid Extraction: Nucleic acids from collected samples are extracted and purified via magnetic bead capture using the SimplicityDx Extraction Kit on the SimplicityDx Extraction System (required but not 3 provided). The SimplicityDx Extraction System automates extraction as follows: Viral capsids/envelopes (or other protection structures) in biological samples are lysed to release nucleic acids; nucleic acids are captured by the silica-coated magnetic beads in

K262789 - Page 3 of 22

{4}

the extraction plate wells; contaminants are washed away through a sequence of wash steps; pure nucleic acids are eluted in Elution buffer.

Preparation of Assay Plate: The SimplicityDx Panel FluA/FluB/RSV plate contains the master mix, primers, and probes required for the amplification and identification of target organisms. Positive and negative control materials are used as amplification controls and must be added to separate wells as designated by the operator. Assay plates are breakaway, allowing for use of partial plates depending on the number of tests to be run. The assay plate or portion of plate to be used is centrifuged to ensure that all of the reagents are at the bottom of the wells. The foil seal from the plate or portion of plate is removed and 14 μL of extracted nucleic acid is added to each well. Once all samples and controls have been added to the plate, the plate is sealed with optical adhesive film, vortexed and then centrifuged to ensure all of the volume is at the bottom of the wells.

Nucleic Acid Amplification and Detection: The prepared assay plate is loaded into the QuantStudio 5 Dx Real-Time PCR System for nucleic acid amplification and detection. The operator initiates the test protocol via user interface (PC running Diomni Enterprise Software), and the QuantStudio 5 Dx Real-Time PCR System automatically executes the test as follows: reverse transcriptase enzyme is activated to generate cDNA from the RNA viruses; Taq polymerase is utilized to amplify sequences of interest if they are present in the well; the 5'-3' exonuclease activity is utilized to cleave the probe and release the fluorophore, allowing it to separate from the quencher and generate the signal that the instrument measures; if sufficient signal is generated by a target, the sample is reported as positive.

# V Substantial Equivalence Information:

A Predicate Device Name(s):
DiaSorin Simplexa Flu A/B & RSV Direct Gen II

B Predicate 510(k) Number(s):
K201505

C Comparison with Predicate(s):

|  Device & Predicate Device(s): | K262789 | K201505  |
| --- | --- | --- |
|  Device Trade Name | SimplicityDx Panel FluA/FluB/RSV | DiaSorin Simplexa Flu A/B & RSV Direct Gen II  |
|  General Device Characteristic Similarities |  |   |
|  Intended Use/Indications For Use | The SimplicityDx Panel FluA/FluB/RSV assay is a multiplex real-time reverse transcriptase polymerase chain reaction (RT-PCR) in vitro diagnostic test intended for the | The DiaSorin Molecular Simplexa Flu A/B & RSV Direct Gen II assay is intended for use on the LIAISON MDX instrument for the in vitro qualitative detection and  |

K262789 - Page 4 of 22

{5}

|   | simultaneous qualitative detection and differentiation of influenza A, influenza B, and/or respiratory syncytial virus (RSV). Nucleic acids are isolated and purified from anterior nasal (AN) swab specimens obtained from individuals exhibiting signs and symptoms of a respiratory tract infection. Clinical signs and symptoms of respiratory viral infection due to influenza A, influenza B, and RSV can be similar. The test is intended to aid in the differential diagnosis of influenza A, influenza B, and RSV in humans in conjunction with other clinical, epidemiologic and laboratory findings and is not intended to detect influenza C. Nucleic acids from the viral organisms identified by this assay are generally detectable in AN swab specimens during the acute phase of infection. Positive results of a specific target are indicative of the presence of viral RNA and may not be the definitive cause of disease. Positive results do not rule out co-infection with other pathogens. Negative results do not preclude influenza A, influenza B, and RSV infection and should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. Performance characteristics for influenza A were | differentiation of influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) RNA in nasopharyngeal swabs (NPS) from human patients with signs and symptoms of respiratory tract infection in conjunction with clinical and epidemiological risk factors. This test is intended for use as an aid in the differential diagnosis of influenza A, influenza B, and RSV viral infections in humans. Negative results do not preclude influenza virus or RSV infection and should not be used as the sole basis for treatment or other patient management decisions. Performance characteristics for influenza A were established with clinical specimens collected during the 2010/2011 influenza season when 2009 H1N1 influenza and H3N2 were the predominant influenza A viruses in circulation. When other influenza A viruses are emerging, performance characteristics may vary. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities,  |
| --- | --- | --- |

K262789 - Page 5 of 22

{6}

|   | established when influenza A/H3 and A/H1 were the predominant influenza A viruses in circulation. Performance of detecting influenza A may vary if other influenza A strains are circulating, or a novel influenza A virus emerges. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health departments for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens. | specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to the state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.  |
| --- | --- | --- |
|  Patient Population | Same | Individuals with exhibiting signs and symptoms of a respiratory tract infection.  |
|  End User | Same | Qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures.  |
|  Prescription or OTC | Same | Prescription Use  |
|  Organism Detected | Same | Influenza A, Influenza B, RSV  |
|  Analyte | Same | RNA  |
|  Technological Principle | Same | Real-time Reverse Transcription PCR (RT-  |

K262789 - Page 6 of 22

{7}

|   |  | PCR)  |
| --- | --- | --- |
|  Test Interpretation | Same | Automated test interpretation  |
|  General Device Characteristic Differences |  |   |
|  Sample Type | Anterior nasal swab Specimens stored in UTM | Nasopharyngeal nasal swab specimens in UTM  |
|  Controls | One negative control and one positive control are run for each plate (external process controls). The assay detects endogenous RNase P present in the specimen as an internal | External Simplexa Flu A/B & RSV Positive Control Pack. Internal control RNA  |

Predetermined Change Control Plan (PCCP):

In addition to the similarities and differences between the candidate device and the predicate device listed in the table above, the candidate device has an authorized predetermined change control plan (PCCP) for modifications to the device to enable the addition of PCR Master Mix that is In Vitro Diagnostic (IVD)-labeled, addition of a real-time PCR instrument that is IVD-labeled, and the addition of different nucleic acid extraction method systems that are IVD-labeled. The PCCP included testing protocols for each modification and pre-defined acceptance criteria. The protocols for the validation of the extraction method and PCR instrument modification were consistent with the studies conducted to determine the acceptability of the current extraction method and PCR instrument through the determination of the Limit of Detection, Reproducibility, Carryover Contamination, and Clinical Studies. The protocols for the Master Mix modifications were consistent with the studies conducted to determine the acceptability of the current Master Mix formulation through determination of the Limit of Detection, Precision, Interfering Substances, and Assay Stability. The acceptance criteria reviewed included the evaluation of overall percent agreement, positive percent agreement, negative percent agreement, and confidence interval evaluation. It was determined that if results for these studies meet acceptance criteria, the use of additional PCR instrumentation, Master Mix modifications, and additional extraction instrumentation with the candidate device would remain as safe and effective as the predicate device. Following verification of these additional modifications, the device labeling will be updated in accordance with the authorized PCCP to provide users with current information regarding compatible real-time PCR instrumentation, extraction instrumentation, and Master Mix modifications for the SimplicityDx Panel FluA/FluB/RSV.

# VI Standards/Guidance Documents Referenced:

- CLSI EP12-3rd Edition. Evaluation of Qualitative Binary Output Examination Performance
- CLSI EP25-A. Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline.

K262789 - Page 7 of 22

{8}

- CLSI EP37-1 \( ^{st} \) Edition. Supplemental Tables for Interference Testing in Clinical Chemistry
- CLSI MM17-2\( ^{nd} \) Edition. Verification and Validation of Multiplex Nucleic Acid Assays
- CLSI EP05-A3 (Reaffirmed September 2019). Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline - Third Edition
- CLSI EP17-A2. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline - Second Edition
- CLSI EP07-3\( ^{rd} \) Edition. Interference Testing in Clinical Chemistry.
- CLSI EP12-A2. User Protocol For Evaluation of Qualitative Test Performance

## VII Performance Characteristics (if/when applicable):

### A Analytical Performance:

#### 1. Precision/Reproducibility:

##### Precision

Within-laboratory precision was performed at a single site with the SimplicityDx Panel FluA/FluB/RSV using a 5-member panel including one negative specimen, two low positive (2x LoD) specimens, and two moderate positive (5x LoD) specimens. The negative sample consisted of simulated negative anterior nasal swab (ANS) matrix without target virus. Positive panel members were created by spiking viral targets into negative simulated ANS matrix at concentration described in Table 1, below. The test was conducted over 12 non-consecutive days, using one lot of SimplicityDx Panel FluA/FluB/RSV plates, one instrument, and two operators. Two replicates of negative specimen, two replicates of low positive specimen (2x LoD), and two replicates of moderate positive specimen (5x LoD) were tested per run. Two runs were performed per day per operator to yield a total of four runs per day and a total of 96 replicates per specimen. The overall agreement rate was \(100\%\) with expected results for all panel members. Results are presented in Table 2 below.

Table 1: Panel Member Strains and Concentrations for Precision Testing

|  Panel Number | Description  |
| --- | --- |
|  1 | Influenza A H1N1/Michigan/45/15 (2x LoD)  |
|  2 | Influenza A H1N1/Michigan/45/15 (5x LoD)  |
|  3 | Influenza B/Brisbane/33/08 and RSV A 1/2015 Isolate #1 (2x LoD)  |
|  4 | Influenza B/Brisbane/33/08 and RSV A 1/2015 Isolate #1 (5x LoD)  |
|  5 | Negative Specimen  |

Table 2: Precision Study Results for the SimplicityDx Panel FluA/FluB/RSV

|  Analyte | Panel Description | n Agreement/ N Valid Tested | % Agreement with Expected Results/ N Valid Test (95% CI)  |
| --- | --- | --- | --- |
|  Influenza A | Low Positive (2x LoD) | 96/96 | 100.0% (96.2%-100.0%)  |
|   |  Moderate Positive (5x LoD) | 96/96 | 100.0% (96.2%-100.0%)  |
|  Influenza B | Low Positive (2x LoD) | 96/96 | 100.0% (96.2%-100.0%)  |
|   |  Moderate Positive (5x LoD) | 96/96 | 100.0% (96.2%-100.0%)  |
|  RSV | Low Positive (2x LoD) | 96/96 | 100.0% (96.2%-100.0%)  |

K262789 - Page 8 of 22

{9}

|   | Moderate Positive (5x LoD) | 96/96 | 100.0% (96.2%-100.0%)  |
| --- | --- | --- | --- |

## Reproducibility

The reproducibility of the SimplicityDx Panel FluA/FluB/RSV was evaluated across three sites using a 5-member panel including one negative specimen, two low positive (2x LoD) specimens, and two moderate positive (5x LoD) specimens. The negative sample consisted of simulated negative anterior nasal swab (ANS) matrix without target virus. Positive panel members were created by spiking viral targets into negative simulated ANS matrix at concentration described in Table 3. Each panel member was tested with two replicates per run. Testing at each site was conducted for 6 non-consecutive days. Each site used three lots of reagents for two days of the six non-consecutive days of testing, during which two operators performed two runs per day with two replicates per run. In total, 144 replicates were tested for each panel member. As shown in Table 4, the percent agreement for all three sites, individually and in combination, achieved 100% concordance with expected results for each panel member.

Table 3. Viral Strains Used for the Reproducibility Study

|  Panel Number | Description  |
| --- | --- |
|  1 | Influenza A H3N2/Kansas/14/17 (2x LoD)  |
|  2 | Influenza A H3N2/Kansas/14/17 (5x LoD)  |
|  3 | Influenza B/Brisbane/33/08 and RSV A 1/2015 Isolate #1 (2x LoD)  |
|  4 | Influenza B/Brisbane/33/08 and RSV A 1/2015 Isolate #1 (5x LoD)  |
|  5 | Negative Specimen  |

Table 4: Reproducibility Study Results for the SimplicityDx Panel FluA/FluB/RSV

|  Assay Target | Panel Description | % Agreement with Expected Results (n Agreement/N Valid Tested) (95% CI)  |   |   |   |
| --- | --- | --- | --- | --- | --- |
|   |   |  Site 1 | Site 2 | Site 3 | Overall  |
|  Influenza A | Low Positive (2x LoD) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (144/144) (97.4%-100%)  |
|   |  Moderate Positive (5x LoD) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (144/144) (97.4%-100%)  |
|  Influenza B | Low Positive (2x LoD) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (144/144) (97.4%-100%)  |
|   |  Moderate Positive (5x LoD) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (144/144) (97.4%-100%)  |
|  RSV A | Low Positive (2x LoD) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (144/144)  |

K262789 - Page 9 of 22

{10}

|   |  |  |  |  | (97.4%-100%)  |
| --- | --- | --- | --- | --- | --- |
|   |  Moderate Positive (5x LoD) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (144/144) (97.4%-100%)  |
|  All targets | Neg | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (48/48) (92.6%-100.0%) | 100% (144/144) (97.4%-100%)  |

## 2. Linearity:

Not applicable.

## 3. Analytical Specificity/Interference:

### a. Inclusivity

Inclusivity of the SimplicityDx Panel FluA/FluB/RSV was evaluated to determine its ability to accurately detect clinically relevant strains, serotypes, or subtypes of influenza A, influenza B, and RSV viruses. Testing was performed using 57 respiratory viral strains consisting of 31 strains of influenza A, 15 strains of influenza B (comprised of both Yamagata and Victoria lineages), and 11 strains of RSV (RSV A and RSV B). Inclusivity panels were created by spiking virus strains at a concentration of 3x LoD in negative pooled clinical ANS matrix and tested in triplicate. For strains not detected at 3x LoD, additional testing at higher concentrations was performed until 100% positivity was observed. The strains evaluated are presented in Table 5 with the lowest concentration achieving 100% detection. This study demonstrates that the SimplicityDx Panel FluA/FluB/RSV is capable of detecting multiple clinically relevant strains of influenza A, influenza B, and RSV.

Table 5: Inclusivity Testing Results for SimplicityDx Panel FluA/FluB/RSV

|  Virus | Strain | Concentration | Detection Rate  |
| --- | --- | --- | --- |
|  Influenza A H1N1 | A/Solomon Islands/3/2006 (NR-41798) | 0.5x LoD | 100% (3/3)  |
|   |  A/Brisbane/59/2007 | 1.3x LoD | 100% (3/3)  |
|   |  A/Wisconsin/629-D02452/2009 | 1.7x LoD | 100% (3/3)  |
|   |  A/Melbourne/1/1946 | 2x LoD | 100% (3/3)  |
|   |  A/Netherlands/2629/2009 (H1N1) pdm09 | 2x LoD | 100% (3/3)  |
|   |  A/New Jersey/8/76 | 2.1x LoD | 100% (3/3)  |
|   |  A/Wilson-Smith/1933 (H1N1) | 2.3x LoD | 100% (3/3)  |
|   |  A1/Denver/1/57 | 2.8x LoD | 100% (3/3)  |
|   |  A/Fort Monmouth/1/1947 | 3x LoD | 100% (3/3)  |
|   |  A/NWS/33 | 3x LoD | 100% (3/3)  |
|   |  A/PR/8/34 | 3x LoD | 100% (3/3)  |
|   |  A/Texas/36/1991 | 3x LoD | 100% (3/3)  |
|   |  A/Beijing/262/1995 | 3x LoD | 100% (3/3)  |

K262789 - Page 10 of 22

{11}

|   | A/Solomon Islands/3/2006 (NR-12281) | 3x LoD | 100% (3/3)  |
| --- | --- | --- | --- |
|   |  A/Georgia/F32551/2012 | 3x LoD | 100% (3/3)  |
|   |  A/New Caledonia/20/1999 | 3.1x LoD | 100% (3/3)  |
|   |  California/07/09 | 3.4x LoD | 100% (3/3)  |
|  Influenza A H3N2 | A/Hong Kong/8/1968 | 1x LoD | 100% (3/3)  |
|   |  A/Aichi/2/1968 | 1.3x LoD | 100% (3/3)  |
|   |  A/Philippines/2/1982 | 2.4x LoD | 100% (3/3)  |
|   |  A/Uruguay/716/2007 | 2.5x LoD | 100% (3/3)  |
|   |  A/Wisconsin/15/2009 | 2.7x LoD | 100% (3/3)  |
|   |  A/Port Chalmers/1/73 | 3x LoD | 100% (3/3)  |
|   |  A/Brisbane/10/2007 | 3x LoD | 100% (3/3)  |
|   |  A/Netherlands/22/2003 | 3x LoD | 100% (3/3)  |
|   |  A/Victoria/3/75 | 3x LoD | 100% (3/3)  |
|   |  A/Wisconsin/67/2005 | 3.3x LoD | 100% (3/3)  |
|   |  A/Sydney/5/1997 | 5.6x LoD | 100% (3/3)  |
|   |  A/Perth/16/09 | 6x LoD | 100% (3/3)  |
|  Influenza A H5N3* | A/duck/Singapore/645/97 | 135,000x LoD | 100% (3/3)  |
|  Influenza A H7N7* | A/equine/Prague/1956 | 135,000x LoD | 100% (3/3)  |
|  Influenza B Victoria | B/Malaysia/2506/2004 | 0.8x LoD | 100% (3/3)  |
|   |  B/Brisbane/60/2008 | 3.2x LoD | 100% (3/3)  |
|   |  B/Ohio/01/2005 | 3.3x LoD | 100% (3/3)  |
|   |  B/Hong Kong/330/2001 | 3.5x LoD | 100% (3/3)  |
|  Influenza B Yamagata | B/Florida/4/2005 | 0.4x LoD | 100% (3/3)  |
|   |  B/Texas/06/2011 | 1.5x LoD | 100% (3/3)  |
|   |  B/Christchurch/33/2004 | 3x LoD | 100% (3/3)  |
|   |  B/Sydney/507/2006 | 6x LoD | 100% (3/3)  |
|  Influenza B Unknown or precedes lineage split | B/Lee/1940 | 1.6x LoD | 100% (3/3)  |
|   |  B/New York/1055/2003 | 2.6x LoD | 100% (3/3)  |
|   |  B/Taiwan/2/1962 | 3x LoD | 100% (3/3)  |
|   |  B/Singapore/3/1964 | 3x LoD | 100% (3/3)  |
|   |  B/Great Lakes/1739/1954 | 3.4x LoD | 100% (3/3)  |
|   |  B/Maryland/1/1959 | 5.2x LoD | 100% (3/3)  |
|   |  B/Allen/45** | 140.6x LoD | 100% (3/3)  |
|  RSV Type A | A2000/3-4 | 1.2x LoD | 100% (3/3)  |
|   |  A2001/3/12 | 1.2x LoD | 100% (3/3)  |
|   |  A/Homo sapiens/ARG/177/2006 | 1x LoD | 100% (3/3)  |
|   |  A1997/12-35 | 3x LoD | 100% (3/3)  |
|   |  A1998/12-21 | 3x LoD | 100% (3/3)  |
|   |  A1998/3-2 | 3.4x LoD | 100% (3/3)  |
|  RSV Type B | 9320 | 1x LoD | 100% (3/3)  |
|   |  RSV-B/WV14617/85 | 1.7x LoD | 100% (3/3)  |
|   |  B1 | 2.7x LoD | 100% (3/3)  |
|   |  ATCC-2012-11 | 3x LoD | 100% (3/3)  |
|   |  18537 | 3x LoD | 100% (3/3)  |

*Non-human influenza A strains. The device is designed for human samples only.

K262789 - Page 11 of 22

{12}

**Distinct from the current circulating population of influenza B.

# b. Cross-Reactivity/Microbial Interference

Cross-reactivity and microbial interference was evaluated for the SimplicityDx Panel FluA/FluB/RSV by wet testing bacteria, viruses, fungi or material found in human upper respiratory tracts with the potential to affect assay performance. A panel of 48 microorganisms, human genomic DNA, and nasal wash were tested either individually or in pools of up to four organisms in the absence and presence of assay target organisms co-formulated at 3x LoD. All samples were prepared in negative pooled clinical ANS matrix and tested in triplicate. The testing concentrations for potentially interfering microorganisms were ≥10⁵ units/mL for viruses and ≥10⁶ units/mL for other microorganisms, unless otherwise noted in the table below. Testing demonstrated 100% analytical specificity for the SimplicityDx Panel FluA/FluB/RSV at the concentrations tested, with no false positive or negative results observed. Results are shown in Table 6.

Table 6: Cross-reactivity and Microbial Interference Results for the SimplicityDx Panel FluA/FluB/RSV

|  Strain | Tested Concentration | Cross-Reactivity Detection Rate | Microbial Interference Detection Rate  |   |   |
| --- | --- | --- | --- | --- | --- |
|   |   |   |  Influenza A | Influenza B | RSV  |
|  Adenovirus Type 1 | 1.0x10⁵ TCID₅₀/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Adenovirus Type 7 | 1.0x10⁵ TCID₅₀/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  *Aspergillus fumigatus* | 1.0x10⁶ CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  *Bordetella parapertussis* | 1.0x10⁶ CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  *Bordetella pertussis* | 1.0x10⁶ CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  *Candida albicans* | 1.0x10⁶ CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  *Chlamydia pneumoniae* | 1.0x10⁶ CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  *Corynebacterium striatum* | 1.0x10⁶ CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Cytomegalovirus | 1.0x10⁵ genomic copies/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Enterovirus Type 71 | 1.0x10⁵ TCID₅₀/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Epstein-Barr virus | 1.0x10⁴ copies/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  *Escherichia coli* | 1.0x10⁶ CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  *Fusobacterium necrophorum* | 1.0x10⁶ CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  *Haemophilus influenzae* | 1.0x10⁶ CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  HSV-1 | 1.0x10⁵ TCID₅₀/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  HSV-2 | 1.0x10⁵ TCID₅₀/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Human Coronavirus 229E | 1.0x10⁴ TCID₅₀/mL | 0/3 | 3/3 | 3/3 | 3/3  |

K262789 - Page 12 of 22

{13}

|  Human Coronavirus HKU1 | \( 1.0 \times 10^{5} \) genomic copies/mL | 0/3 | 3/3 | 3/3 | 3/3  |
| --- | --- | --- | --- | --- | --- |
|  Human Coronavirus NL63 | \( 1.0 \times 10^{5} \) TCID\(_{50}\)/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Human Coronavirus OC43 | \( 1.0 \times 10^{5} \) TCID\(_{50}\)/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Human metapneumovirus A | \( 1.0 \times 10^{5} \) TCID\(_{50}\)/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Human Metapneumovirus B | \( 1.0 \times 10^{4} \) TCID\(_{50}\)/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Human Parainfluenza virus Type 1 | \( 1.0 \times 10^{5} \) TCID\(_{50}\)/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Human Parainfluenza virus Type 2 | \( 1.0 \times 10^{5} \) TCID\(_{50}\)/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Human Parainfluenza virus Type 3 | \( 1.0 \times 10^{5} \) TCID\(_{50}\)/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Human Parainfluenza virus Type 4 | \( 1.0 \times 10^{5} \) TCID\(_{50}\)/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Lactobacillus species | \( 1.0 \times 10^{6} \) genomic copies/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Legionella pneumophila | \( 1.0 \times 10^{6} \) CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Measles Virus | \( 1.0 \times 10^{5} \) TCID\(_{50}\)/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  MERS Coronavirus | \( 1.0 \times 10^{5} \) genomic copies/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Moraxella catarrhalis | \( 1.0 \times 10^{6} \) CFU/vial | 0/3 | 3/3 | 3/3 | 3/3  |
|  Mumps | \( 1.0 \times 10^{5} \) TCID\(_{50}\)/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Mycobacterium tuberculosis | \( 1.0 \times 10^{6} \) CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Mycoplasma genitalium | \( 1.0 \times 10^{6} \) copies/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Mycoplasma pneumoniae | \( 1.0 \times 10^{6} \) CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Neisseria meningitidis | \( 1.0 \times 10^{6} \) genomic copies/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Neisseria mucosa | \( 1.0 \times 10^{6} \) genomic copies/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Pneumocystis jirovecii | \( 1.0 \times 10^{6} \) CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Pseudomonas aeruginosa | \( 1.0 \times 10^{6} \) CFU/mL | 0/3 | 3/3 | 3/3 | 3/3  |

K262789 - Page 13 of 22

{14}

|  Rhinovirus Type 1A | \( {1.0} \times {10}^{5}{\mathrm{{TCID}}}_{50}/\mathrm{{mL}} \) | 0/3 | 3/3 | 3/3 | 3/3  |
| --- | --- | --- | --- | --- | --- |
|  SARS-CoV-1 | \( {1.0} \times {10}^{5} \) genomic copies/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Staphylococcus aureus | \( {1.0} \times {10}^{6}\mathrm{{CFU}}/\mathrm{{mL}} \) | 0/3 | 3/3 | 3/3 | 3/3  |
|  Staphylococcus epidermidis | \( {1.0} \times {10}^{6}\mathrm{{CFU}}/\mathrm{{mL}} \) | 0/3 | 3/3 | 3/3 | 3/3  |
|  Streptococcus pneumoniae | \( {1.0} \times {10}^{6}\mathrm{{CFU}}/\mathrm{{mL}} \) | 0/3 | 3/3 | 3/3 | 3/3  |
|  Streptococcus pyogenes | \( {1.0} \times {10}^{6}\mathrm{{CFU}}/\mathrm{{mL}} \) | 0/3 | 3/3 | 3/3 | 3/3  |
|  Streptococcus salivarius | \( {1.0} \times {10}^{6}\mathrm{{CFU}}/\mathrm{{mL}} \) | 0/3 | 3/3 | 3/3 | 3/3  |
|  Human Genomic DNA | \( {1.0} \times {10}^{5} \) copies/mL | 0/3 | 3/3 | 3/3 | 3/3  |
|  Nasal Wash | Not applicable | 0/3 | 3/3 | 3/3 | 3/3  |

### c. Interfering Substances

The purpose of this study was to determine the analytical reactivity of the SimplicityDx Panel FluA/FluB/RSV in the presence of endogenous and exogenous substances that may commonly be found in the upper respiratory tract. The assay was evaluated with potentially interfering substances in the presence and absence of target analyte. The study used two strains of influenza A, two strains of influenza B, and two strains of RSV. The strains and pooling scheme used for this study are presented below in Table 7. Positive specimens were prepared in pooled negative ANS clinical matrix with two co-formulated pools of influenza A, influenza B, and RSV viruses at a concentration of 3x LoD. For negative analyte samples, potentially interfering substances were combined with pooled negative ANS clinical matrix without target analytes. Triplicate of each potential interferant sample were tested in the presence and absence of target organisms. No substances evaluated interfered with test performance at the concentrations tested. As expected, false positive results for influenza A and influenza B were observed in the presence of FluMist. The substances evaluated and results of the study are presented in Table 8.

Table 7: Organism and Pooling Scheme for Interfering Substances Study

|  Pool | Virus | Strain  |
| --- | --- | --- |
|  1 | FluA H1N1 | Michigan/45/15  |
|  2 | FluA H3N2 | Kansas/14/17  |
|  1 | FluB | B/Brisbane/33/08  |
|  2 | FluB | B/Texas/6/11  |
|  1 | RSV A | RSV A 1/2015 Isolate #1  |
|  2 | RSV B | RSV B-3/2015 Isolate #1  |

Table 8. Potential Interferent Substances Results for the SimplicityDx Panel FluA/FluB/RSV

|  Substance |  | Detection Rate  |
| --- | --- | --- |

K262789 - Page 14 of 22

{15}

|   | Conc. Tested | No Virus Control | Influenza A H3N2 Kansas/14 / 17 | Influenza A H1N1 Michigan/ 45/15 | Influenza B Brisbane/ 33/08 | Influenza B Texas/ 6/11 | RSVA 1/2015 Isolate 1 | RSV B 3/2015 Isolate #1  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  No substance control | NA | 75/75 | 75/75 | 75/75 | 75/75 | 75/75 | 75/75 | 75/75  |
|  Nasal Gel | 5% v/v | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Dextromethorphan | 5% v/v | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Phenol | 5% v/v | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Zicam | 15% v/v | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Oxymetazoline | 15% v/v | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Phenylephrine | 15% v/v | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Saline | 15% v/v | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Beclomethasone | 666.7 μg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Dexamethasone | 1.5 mg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Flunisolide | 2 mg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Triamcinolone acetonide | 5 μg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Budesonide | 5 μg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Mometasone furoate | 5 μg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Fluticasone propionate | 5 μg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Zanamivir | 7.5 mg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Oseltamivir | 7.5 mg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Mupirocin | 10 mg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Tobramycin | 4 μg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  FluMist | 6.7% v/v | \( 3/3^a \) | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Mucin | 5 mg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  PBMC | \( 1 \times 10^6 \) cells/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Blood | 5 % v/v | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Chloraseptic lozenge | 3 mg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |
|  Cepacol lozenge | 3 mg/mL | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | 3/3  |

NA=Not Applicable

\( ^{a} \)  As expected, the no virus control detected amplification for influenza A and influenza B in the presence of FluMist.

3/3 negative results were observed for RSV.

### d. Competitive Interference

The purpose of this study was to evaluate the potential competitive interference between target analytes of the SimplicityDx Panel FluA/FluB/RSV. Testing was conducted by spiking influenza A, influenza B, or RSV at concentrations of 3x LoD in the presence of a different target analyte at high concentrations ( \( 10^{5} \) copies/mL or higher). All samples

K262789 - Page 15 of 22

{16}

were prepared in pooled negative ANS clinical matrix. Target strains were also tested in the absence of the competitive strains and competitive strains were tested in the absence of target strains for control conditions. Three replicates of each condition were tested. One strain of influenza A (H3N2 Kansas/14/17) and influenza B (B/Brisbane/33/08), and two strains of RSV (RSV A 1/2015 Isolate #1 and RSV B-3/2015 Isolate #1) were tested. Study results showed that influenza A Kansas/14/17 at concentrations above 1.21x10⁵ copies/mL inhibited detection of RSV A and B at 3x LoD. In addition, influenza B Brisbane/33/08 inhibited detection of influenza A at concentrations above 1.41x10⁵ copies/mL. Results are summarized in Table 9.

Table 9: Competitive Interference Results for the SimplicityDx Panel FluA/FluB/RSV

|  Interferent | Analyte (3x LoD) | Interferent Concentration Tested | Interference Observed  |
| --- | --- | --- | --- |
|  Influenza A | Influenza B | 1.01x10⁶ copies/mL | None  |
|   |   |  1.21x10⁵ copies/mL | None  |
|   |  RSV A | 1.01x10⁶ copies/mL | Interference Observedᵃ  |
|   |   |  1.21x10⁵ copies/mL | None  |
|   |  RSV B | 1.01x10⁶ copies/mL | Interference Observedᵃ  |
|   |   |  1.21x10⁵ copies/mL | None  |
|  Influenza B | Influenza A | 1.12x10⁶ copies/mL | Interference Observedᵇ  |
|   |   |  1.41x10⁵ copies/mL | None  |
|   |  RSV A | 1.12x10⁶ copies/mL | None  |
|   |   |  1.41x10⁵ copies/mL | None  |
|   |  RSV B | 1.12x10⁶ copies/mL | None  |
|   |   |  1.41x10⁵ copies/mL | None  |
|  RSV A | Influenza A | 1.10x10⁶ copies/mL | None  |
|   |   |  1.04x10⁵ copies/mL | None  |
|   |  Influenza B | 1.10x10⁶ copies/mL | None  |
|   |   |  1.04x10⁵ copies/mL | None  |
|  RSV B | Influenza A | 1.51x10⁶ copies/mL | None  |
|   |   |  1.02x10⁵ copies/mL | None  |
|   |  Influenza B | 1.51x10⁶ copies/mL | None  |
|   |   |  1.02x10⁵ copies/mL | None  |

ᵃ Interference was observed for influenza A Kansas/14/17 with RSV at concentrations above 1.21x10⁵ copies/mL. Detection was 33.3% (1/3) for RSV A and 66.7% (2/3) for RSV B.

ᵇ Interference was observed for influenza B Brisbane/33/08 with influenza A at concentrations above 1.41x10⁵ copies/mL. Detection was 33.3% (1/3).

#### 4. Detection Limit:

Limit of detection (LoD) studies were conducted to determine the lowest detectable concentration of influenza A virus, influenza B virus and RSV at which ≥95% of all replicates test positive. First, a preliminary LoD was determined by testing serial 2-fold dilutions of quantified virus stocks in a pooled ANS clinical matrix, with the lowest concentration showing 100% detection across three replicates being selected. This preliminary LoD was then validated in a confirmatory step by testing a minimum of 21 replicates at concentrations at, 2-fold above, and 2-fold below this level. The final LoD was confirmed as the lowest concentration that achieved a positive detection rate of at least 95% (e.g., 20 out of 21 replicates). The confirmed LoD for each strain is summarized in Table 10.

K262789 - Page 16 of 22

{17}

Table 10: Summary of Confirmed LoD for the SimplicityDx Panel FluA/FluB/RSV

|  Organism | LoD (copies/mL) | Mean Ct  |
| --- | --- | --- |
|  FluA H3N2 Kansas/14/17 | 114 | 35.70  |
|  FluA H3N2 Hong Kong/2671/19 | 3258 | 34.98  |
|  FluA H3N2 Darwin/9/21 | 223 | 34.66  |
|  FluA H1N1 Michigan/45/15 | 152 | 34.84  |
|  FluB Brisbane/33/08 (Yamagata) | 62 | 36.17  |
|  FluB Texas/6/11 (Victoria) | 36 | 35.67  |
|  RSVA 1/2015 Isolate #1 | 229 | 35.14  |
|  RSVB 3/2015 Isolate #1 | 718 | 34.39  |
|  RSVB CH93(18)-18 | 347 | 34.17  |

The LoD for co-analyte spiked samples was also evaluated and shown to be equivalent to single analyte spiked samples.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

a. Controls

The SimplicityDx Panel FluA/FluB/RSV controls consist of internal processing control, negative control, and positive control.

i. Internal Processing Control (IPC): The RNase P (RP) target is the IPC. The IPC confirms that a sufficient amount of material was collected to generate an accurate and interpretable result. A positive result for the IPC test also confirms that sample collection, sample processing, and the PCR reaction occurred as intended.

ii. External Controls: The following controls have been validated and are suitable for use with the SimplicityDx Panel FluA/FluB/RSV on the QuantStudio 5 Dx Real-Time PCR System.

Zeptometrix Positive Control:

- NATtrol Flu/RSV/SARS-CoV-2 Positive Control Swab, IVD (Zeptometrix REF: NATFRC-SW-IVD)

Each kit contains 12 swabs that can be resuspended in 3 mL of transport medium and processed similar to a sample.

UTM Negative Control

- UTM (Universal Transport Medium) may be prepared and used as negative control.

b. Specimen Stability

Specimen stability study was conducted to evaluate the stability of anterior nasal samples collected in Universal Transport Medium (UTM) under various storage conditions and after freeze-thaw cycles. Results of the study support the following:

- Samples collected in UTM can be stored for up to 48 hours at ambient temperature (15-30°C)
- Samples collected in UTM can be stored for up to 7 days at 2-8°C
- Samples collected in UTM can be stored for up to 30 days at -70°C or colder and undergo 2 freeze/thaw cycles.

K262789 - Page 17 of 22

{18}

- Nucleic acid sample extracts can be stored at room temperature for up to 2 hours.
- Nucleic acid sample extracts can be stored refrigerated (2-8°C) for up to 8 hours or -15°C to -25°C or ≤-70°C and undergo 2 freeze/thaw cycles.

# c. Reagent Stability

SimplicityDx Panel FluA/FluB/RSV plates are stable when stored at -15°C to -25°C for up to 6 months prior to use.

# 6. Assay Cut-Off:

The assay cut-off foreach target was determined based on analysis parameters defined in the Diomni software. The analysis parameters utilized include Cq (Ct), delta RN, Cq confidence, and signal-to-noise ratio. The default parameters defined by the Diomni software algorithm were used and subsequently refined during the development process. Clinical samples and spiked samples in clinical matrix were used to develop the algorithm. These studies were used to determine that the algorithm was sufficient to differentiate positive specimens. The analysis parameters are included in the assay definition file (ADF) and automatically applied.

# 7. Carryover

A study was conducted to demonstrate that carryover contamination does not occur in the Simplicity Dx Extraction System or the SimplicityDx Panel FluA/FluB/RSV on the QuantStudio 5 Dx System. Positive samples were prepared with one strain of influenza B in simulated negative matrix at a concentration of 3.8x10⁵ TCID₅₀/mL. Negative samples were prepared in simulated negative matrix without the target organism.

To evaluate the extraction carry-over, eight high-concentration FluB-positive and eight FluB-negative specimens were alternated across an extraction plate in a checkerboard pattern and then tested on the assay. Six extraction runs were completed by two operators who performed three PCR runs utilizing three SimplicityDx Extraction instruments. All 48 positive specimens and 48 negative specimens were correctly reported following extraction.

To evaluate PCR carry-over, 20 high-concentration FluB-positive specimens and 20 FluB-negative specimens were tested in checkerboard layout across plate wells. Six PCR runs were completed with two operators who performed three PCR runs utilizing three QuantStudio 5 Dx instruments. All one 120 positive specimens and 120 negative specimens were correctly reported by the assay for assay carry-over.

No carry-over or contamination of either extraction or assay setup were observed in this study

# B Comparison Studies:

1. Method Comparison with Predicate Device:
Not applicable.

2. Matrix Comparison:

K262789 - Page 18 of 22

{19}

The matrix equivalency study was designed to compare the performance between contrived specimens made in naturally occurring negative clinical matrix and simulated negative matrix. Both the pooled negative clinical matrix and the simulated matrix were spiked with a co-formulated mix of influenza A H1N1/Michigan/45/15, influenza B/Brisbane/33/08, and RSV A-1/2015 Isolate #1 viruses. Positive specimens were prepared at two concentrations: a moderate positive at 5x LoD and a low positive at 2x LoD. For each matrix type, the study tested 10 replicates of the 5x LoD specimens, 30 replicates of the 2x LoD specimens, and 10 negative specimens without any virus. As shown in Table 11, all samples in each matrix type obtained expected results, demonstrating equivalent performance between samples prepared in natural clinical matrix and simulated matrix.

Table 11: Summary of Matrix Equivalency Results

|  Sample | % Correct Calls(# correct calls/ # replicates tested)  |   |
| --- | --- | --- |
|   |  Clinical Matrix | Simulated Matrix  |
|  Negative | 100% (10/10) | 100% (10/10)  |
|  Flu A 2x LoD | 100% (30/30) | 100% (30/30)  |
|  Flu A 5x LoD | 100% (10/10) | 100% (10/10)  |
|  Flu B 2x LoD | 100% (30/30) | 100% (30/30)  |
|  Flu B 5x LoD | 100% (10/10) | 100% (10/10)  |
|  RSV 2x LoD | 100% (30/30) | 100% (30/30)  |
|  RSV 5x LoD | 100% (10/10) | 100% (10/10)  |

### C Clinical Studies:

#### 1. Clinical Sensitivity:

The clinical performance of the SimplicityDx Panel FluA/FluB/RSV was evaluated in a prospective all comers clinical study using residual anterior nasal swabs (ANS) specimens collected in universal transport media (UTM) from patients with signs and symptoms of respiratory infection. The study was conducted at multiple geographically diverse sites in the United States during November 2024 through April 2025. A total of 872 prospectively collected samples were tested fresh (Category I), of which 197 were excluded due to a contamination event at one of the testing sites, and six were excluded due to invalid results from both initial and repeat testing. A total of 269 prospectively collected samples were frozen and later tested (Category II), of which 15 were excluded due to invalid results from both initial and repeat testing and nine samples were excluded due to protocol deviations, primarily related to sample handling issues such as delayed shipment or insufficient volume. Positive percent agreement (PPA) and negative percent agreement (NPA) were calculated by comparing results of the SimplicityDx Panel FluA/FluB/RSV to results of an FDA-cleared molecular assay. The demographics and performance for the evaluable subjects are described in Table 12 – Table 14. The initial invalid rate was 12.5% (114 samples) and on repeat testing the final invalid rate was 2.6% (24 samples).

Table 12: Demographics of Subjects from Fresh Prospective Population

|  Characteristic | Clinical Samples N=669  |
| --- | --- |
|  Age |   |
|  Mean (SD) | 35.1 (29.20)  |
|  Median | 31  |

K262789 - Page 19 of 22

{20}

|  SD | 28.02  |
| --- | --- |
|  Minimum | 0  |
|  Maximum | 90  |
|  **Age Group** | **n (%)**  |
|  Birth to 5 years | 165 (24.7%)  |
|  6 to 21 years | 136 (20.3%)  |
|  22 to 59 years | 161 (24.1%)  |
|  ≥ 60 years | 207 (30.9%)  |
|  **Sex** | **n (%)**  |
|  Female | 360 (53.8%)  |
|  Male | 309 (46.2%)  |
|  **Race** | **n (%)**  |
|  American Indian or Alaskan Native | 56 (11.8%)  |
|  Asian | 5 (1.1%)  |
|  Black/African American | 69 (14.5%)  |
|  White | 300 (63.0%)  |
|  More than one race ^{a} | 3 (0.6%)  |
|  Unknown/Prefer not to answer | 41 (8.6%)  |
|  Missing | 2 (0.4%)  |
|  None of the information is available | 193 (28.8%)  |
|  **Ethnicity** | **n (%)**  |
|  Hispanic/Latino | 79 (16.6%)  |
|  Not Hispanic/Latino | 133 (27.9%)  |
|  Unknown/Prefer not to answer | 264 (55.5%)  |
|  None of the information is available | 193 (28.8%)  |

$^{a}$ If more than one race is reported for a patient, he/she is described only in this category and is not described in the other race categories.

**Table 13:** Demographics of Subjects from Frozen Prospective Population

|  **Characteristic** | **Clinical Samples N=245**  |
| --- | --- |
|  **Age** |   |
|  Mean (SD) | 43.5 (24.59)  |
|  Median | 44  |
|  SD | 28.02  |
|  Minimum | 0  |
|  Maximum | 92  |
|  **Age Group** | **n (%)**  |
|  Birth to 5 years | 11 (4.5%)  |
|  6 to 21 years | 54 (22.0%)  |
|  22 to 59 years | 100 (40.8%)  |
|  ≥ 60 years | 80 (32.7%)  |
|  **Sex** | **n (%)**  |
|  Female | 140 (57.1%)  |
|  Male | 105 (42.9%)  |
|  **Race** | **n (%)**  |
|  White | 195 (79.6%)  |
|  Black/African American | 1 (0.4%)  |

K262789 - Page 20 of 22

{21}

|  Unknown/Prefer not to answer | 4 (1.6%)  |
| --- | --- |
|  None of the information is available | 45 (18.4%)  |

Table 14: Clinical Performance of the SimplicityDx Panel FluA/FluB/RSV

|  Analyte |  |   |   |   | Positive Percent Agreement |   |   | Negative Percent Agreement  |   |   |   |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|   |   |  TP | FP | FN | TN | TP/(TP+FN) | % | 95% CI | TN/(TN+FP) | % | 95% CI  |
|  Influenza A | Fresh | 48 | 2 | 2 | 617 | 48/50 | 96.0 | 86.5-98.9 | 617/619 | 99.7 | 98.8-99.9  |
|   |  Frozen | 25 | 1 | 0 | 219 | 25/25 | 100.0 | 86.7-100.0 | 219/220 | 99.5 | 97.5-99.9  |
|   |  Overall | 73 | \( 3^b \) | \( 2^a \) | 839 | 73/75 | 97.3 | 90.8-99.3 | 839/842 | 99.6 | 99.0-99.9  |
|  Influenza B | Fresh | 7 | 0 | 0 | 662 | 7/7 | 100.0 | 64.6-100.0 | 662/662 | 100.0 | 99.4-100.0  |
|   |  Frozen | 33 | 1 | 0 | 211 | 33/33 | 100.0 | 89.6-100.0 | 211/212 | 99.5 | 97.4-99.9  |
|   |  Overall | 40 | \( 1^c \) | 0 | 873 | 40/40 | 100.0 | 81.2-100.0 | 873/874 | 99.9 | 99.4-100.0  |
|  RSV | Fresh | 36 | 12 | 0 | 621 | 36/36 | 100.0 | 90.4-100.0 | 621/633 | 98.1 | 96.7-98.9  |
|   |  Frozen | 6 | 2 | 0 | 237 | 6/6 | 100.0 | 61.0-100.0 | 237/239 | 99.2 | 97.0-99.8  |
|   |  Overall | 42 | \( 14^d \) | 0 | 858 | 42/42 | 100.0 | 91.6-100.0 | 858/872 | 98.4 | 97.3-99.0  |

\( ^{a} \)  Discrepant test results based on a U.S. FDA-cleared molecular respiratory panel: 0/2 FluA positive; 2/2 FluA negative

\( ^{b} \)  Discrepant test results based on a U.S. FDA-cleared molecular respiratory panel: 0/2 FluA positive; 2/2 FluA negative; 1 discordant test was not performed due to insufficient sample volume

\( ^{c} \)  Discrepant test results based on a U.S. FDA-cleared molecular respiratory panel: 1/1 FluB positive; 0/1 FluB negative

\( ^{d} \)  Discrepant test results based on a U.S. FDA-cleared molecular respiratory panel: 2/13 RSV positive; 11/13 RSV negative; 1 discordant test was not performed due to insufficient sample volume

#### 2. Clinical Specificity:

See Clinical Sensitivity above.

#### 3. Clinical Cut-Off:

Not applicable

#### 4. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):

Not applicable.

### D Expected Values/Reference Range:

The SimplicityDx Panel FluA/FluB/RSV prospective clinical study included a total of 914 evaluable ANS specimens (Category I and Category II). The number and percentage of samples positive for influenza A, influenza B, and RSV as determined by the SimplicityDx Panel FluA/FluB/RSV are presented in Table 15 and Table 16 below.

Table 15: SimplicityDx Panel FluA/FluB/RSV Expected Results by Site for Category I Samples

|  Site | Influenza A |   | Influenza B |   | RSV  |   |
| --- | --- | --- | --- | --- | --- | --- |
|   |  # of positives | % positivity | # of positives | % positivity | # of positives | % positivity  |
|  Site 1 | 18 | 10.6% (18/170) | 3 | 1.8% (3/170) | 16 | 9.4% (16/170)  |
|  Site 2 | 28 | 7.6% (28/370) | 1 | 0.3% (1/370) | 27 | 7.3% (27/370)  |

K262789 - Page 21 of 22

{22}

|  Site 3 | 4 | 3.1% (4/129) | 3 | 2.3% (3/129) | 5 | 3.9% (5/129)  |
| --- | --- | --- | --- | --- | --- | --- |
|  Total | 50 | 7.5% (50/669) | 7 | 1.0% (7/669) | 48 | 7.2% (48/669)  |

Table 16: SimplicityDx Panel FluA/FluB/RSV Expected Results by Site for Category II Samples

|  Site | Influenza A |   | Influenza B |   | RSV  |   |
| --- | --- | --- | --- | --- | --- | --- |
|   |  # of positives | % positivity | # of positives | % positivity | # of positives | % positivity  |
|  Site 1 | 22 | 31.0% (22/71) | 8 | 11.3% (8/71) | 3 | 4.2% (3/71)  |
|  Site 2 | 0 | 0.0% (0/30) | 2 | 6.7% (2/30) | 0 | 0.0% (0/30)  |
|  Site 3 | 4 | 4.7% (4/86) | 24 | 27.9% (24/86) | 4 | 4.7% (4/86)  |
|  Site 4 | 0 | 0.0% (0/58) | 0 | 0.0% (0/58) | 1 | 1.7% (1/58)  |
|  Total | 26 | 10.6% (26/245) | 34 | 13.9% (34/245) | 8 | 3.3% (8/245)  |

### VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

### IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

K262789 - Page 22 of 22

---

**Source:** [https://fda.innolitics.com/device/K262789](https://fda.innolitics.com/device/K262789)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com
